entertainment -WSS

entertainment

author：Wikipedia 2025-08-23 03:45:36 - browse：95

Stephen Quake: "Our North Star for the next decade is understanding the mysteries of the cell." Chan Zuckerberg Initiative

SAN DIEGO — Decades ago, as a young physics Ph.D. student, Stephen Quake stumbled into the messy, dazzlingly complicated world of biology — and he’s stayed there ever since.

Quake, a professor of bioengineering and applied physics at Stanford, is a prolific academic whose discoveries have fueled the field of blood-based prenatal testing and the use of microfluidic chips, which allow scientists to quickly analyze DNA, RNA, proteins, and cells. He’s also head of science for the Chan Zuckerberg Initiative, or CZI, a company Mark Zuckerberg and Priscilla Chan founded in 2015 with the expressed intent to help “cure, prevent or manage all diseases by the end of this century.” The organization funds academic research and operates three biohubs in San Francisco, Chicago, and New York, each centered on goals such as building cells that can survey the body for signs of disease or deciphering the signals that drive inflammatory disease.

STAT sat down with Quake in front of an audience during the annual meeting of the Biotechnology Innovation Organization for a fireside chat about his pivot into the life sciences — and his second unexpected journey into the world of philanthropy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Histogen: Failed biotech offers rare public look inside

WSS

First medicine developed to treat MASH expected to be approved soon

VC firm General Catalyst wants to buy a health system

Bristol 'take

RSV shot was 90% effective at preventing hospitalizations in kids

Chemotherapy drug shortage eases slightly but still widespread

Precocious puberty in girls comes with mental health risks

explore

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

focus

Virginia high school admissions case could be legal follow

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

How one medical school became remarkably diverse

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The problem with charging patients to message their doctors

Malaria cases in Florida and Texas: Here’s what you need to know

Change Healthcare cyberattack prompts Medicare loan program

Novavax promises a turnaround & Lilly roils the obesity market

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

focus

Novo Nordisk obesity pill bests Wegovy in early trial

Analysis of telehealth claims data suggest service duplication

FDA rejects Alnylam's heart disease treatment over insufficient data

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

NEJM study link tiny plastics in blood vessels to heart problems

Air quality improving but still lags in Black, Hispanic communities

hotspot

leisure time

focus

focus